Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell and exosome-based therapies, primarily focusing on deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy. Its proprietary platforms target muscle degeneration and inflammation through immunomodulatory and regenerative mechanisms. Capricor’s business model centers on advancing clinical development, manufacturing, and partnering for commercialization in key markets including the U.S. and Japan.
This description was generated via AI from an annual report. Updated about 1 year ago.